0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BMS21009

Target 4-1BB monoclonal antibody

Active
  • Project profile
    Project name: Target 4-1BB monoclonal antibody
    Indications: Tumors such as breast cancer, bladder cancer, NSCLC,DLBCL.
    Research phase: Pre-IND application
    Cooperation demands: Project authorization, transfer or co-development. (project’s company is seeking for external cooperation to accelate drug research and development.)
  • Highlights
    1. Project’s activation response depends on FcγR- crosslinking, with high therapeutic effectiveness and low toxicity;
    2. Head-to-head experiment with Utomilumab( Highest clinical phase of anti 4-1BB antibody globaly) was conducted: 1) this project’s effectiveness was better than Utomilumab’s; 2) this project’s safety data was equivalent to Utomilumab’s; 3) this project exhibited outstanding safety in Cynomolgus Monkeys’ toxicology experiment;
    3. Complete CMC development: expression level was more than 6g/L; quality assessment, pilot scale production and safety evaluation were completed;
    4. Pre-clinical data was better than Utomilumab’s which has BIC potential.
  • Project Introduction

    1. Drug type: Monoclonal antibody;

    2. Mechanism: The tumor inhibition mechanism of this project is to regulate the function of key immune cells responding to cancer cells, such as stimulating and activating effector T cells(mainly stimulating CD8+ T cells to produce INFγ), NKT and APCs(such as macrophage) to selectively kill the cancer cells;

    3. Indications: Tumors such as breast cancer,bladder cancer, NSCLC,DLBCL;

    4. Research phase: Pre-IND application ;

    5. Research progress: The following studies have been completed:Affinity, in vitro and in vivo functional validation, in vitro pharmacodynamics,in vivo pharmacodynamics and toxicology,CMC development.The highest expression level of stable cell line was 6g/L.

Comments (0)